Abstract
Target size is often the dose-limiting factor in radiotherapy of lung cancer, forcing one to accept a sub-optimal plan that balances competing risk factors of tumor recurrence and organ toxicity. In this study we investigate a novel adaptive radiotherapy of lung cancer that monitors and takes advantage of tumor regression during the course of radiation using PET/CT imaging.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have